Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 70 | 2024 | 5713 | 5.480 |
Why?
|
Killer Cells, Natural | 32 | 2024 | 2206 | 5.110 |
Why?
|
Graft vs Host Disease | 45 | 2024 | 3044 | 4.050 |
Why?
|
Cyclophosphamide | 30 | 2024 | 2226 | 3.940 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 10 | 2021 | 263 | 3.630 |
Why?
|
Leukemia, Myeloid, Acute | 33 | 2024 | 3620 | 3.300 |
Why?
|
Transplantation Conditioning | 27 | 2024 | 1600 | 2.750 |
Why?
|
Hematologic Neoplasms | 14 | 2024 | 1905 | 1.740 |
Why?
|
Interleukin-15 | 7 | 2024 | 185 | 1.680 |
Why?
|
Lymphocyte Depletion | 5 | 2020 | 605 | 1.570 |
Why?
|
Immunotherapy, Adoptive | 12 | 2024 | 1508 | 1.390 |
Why?
|
Myelodysplastic Syndromes | 12 | 2024 | 1399 | 1.320 |
Why?
|
Immunologic Memory | 7 | 2024 | 1374 | 1.320 |
Why?
|
HLA Antigens | 8 | 2021 | 1337 | 1.300 |
Why?
|
Cord Blood Stem Cell Transplantation | 5 | 2021 | 305 | 1.230 |
Why?
|
Transplantation, Homologous | 20 | 2024 | 4834 | 1.230 |
Why?
|
Leukemia | 5 | 2021 | 1526 | 1.050 |
Why?
|
Tissue Donors | 9 | 2022 | 2389 | 1.020 |
Why?
|
Bone Marrow Diseases | 2 | 2017 | 234 | 0.920 |
Why?
|
Histocompatibility | 5 | 2019 | 322 | 0.920 |
Why?
|
Cytokines | 7 | 2024 | 7445 | 0.900 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2021 | 631 | 0.890 |
Why?
|
Myeloablative Agonists | 4 | 2019 | 210 | 0.830 |
Why?
|
Receptors, IgG | 3 | 2015 | 564 | 0.830 |
Why?
|
Opportunistic Infections | 4 | 2023 | 375 | 0.790 |
Why?
|
Cytomegalovirus Infections | 6 | 2023 | 839 | 0.770 |
Why?
|
Multiple Myeloma | 5 | 2024 | 5192 | 0.760 |
Why?
|
Lymphocyte Transfusion | 2 | 2020 | 232 | 0.700 |
Why?
|
Cytotoxicity, Immunologic | 7 | 2024 | 1355 | 0.620 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2024 | 1362 | 0.620 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2021 | 225 | 0.600 |
Why?
|
T-Lymphocytes | 12 | 2024 | 10267 | 0.570 |
Why?
|
Neoplasms | 10 | 2024 | 22385 | 0.560 |
Why?
|
Cytomegalovirus | 3 | 2021 | 754 | 0.550 |
Why?
|
Epitopes | 3 | 2020 | 2525 | 0.550 |
Why?
|
Sarcoma, Myeloid | 1 | 2017 | 52 | 0.540 |
Why?
|
Tongue Diseases | 1 | 2017 | 69 | 0.540 |
Why?
|
Salvage Therapy | 4 | 2021 | 1277 | 0.510 |
Why?
|
Interleukin-2 | 2 | 2022 | 1894 | 0.510 |
Why?
|
Azacitidine | 5 | 2024 | 336 | 0.510 |
Why?
|
Humans | 122 | 2024 | 768393 | 0.470 |
Why?
|
Lymphocyte Subsets | 1 | 2015 | 313 | 0.460 |
Why?
|
Tongue | 1 | 2017 | 406 | 0.440 |
Why?
|
Leukemia, Myeloid | 1 | 2016 | 693 | 0.430 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2017 | 618 | 0.420 |
Why?
|
Acetates | 1 | 2014 | 317 | 0.420 |
Why?
|
Disease-Free Survival | 12 | 2021 | 6856 | 0.410 |
Why?
|
Serum Albumin | 1 | 2016 | 676 | 0.410 |
Why?
|
Recurrence | 10 | 2024 | 8506 | 0.380 |
Why?
|
Virus Activation | 1 | 2013 | 322 | 0.380 |
Why?
|
Aged | 45 | 2024 | 171562 | 0.380 |
Why?
|
ADAM Proteins | 1 | 2013 | 238 | 0.380 |
Why?
|
Adult | 57 | 2024 | 223640 | 0.370 |
Why?
|
Hematologic Diseases | 1 | 2015 | 499 | 0.370 |
Why?
|
Lymphocyte Activation | 5 | 2022 | 5496 | 0.370 |
Why?
|
Middle Aged | 50 | 2024 | 223491 | 0.360 |
Why?
|
Siblings | 7 | 2021 | 829 | 0.360 |
Why?
|
Immunophenotyping | 1 | 2015 | 1866 | 0.350 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2015 | 507 | 0.350 |
Why?
|
Young Adult | 28 | 2024 | 60049 | 0.350 |
Why?
|
ABO Blood-Group System | 1 | 2013 | 381 | 0.350 |
Why?
|
Retrospective Studies | 35 | 2024 | 81801 | 0.340 |
Why?
|
Histocompatibility Testing | 4 | 2020 | 716 | 0.340 |
Why?
|
Immunocompromised Host | 2 | 2017 | 863 | 0.340 |
Why?
|
Encephalitis, Herpes Simplex | 1 | 2009 | 65 | 0.320 |
Why?
|
Hepatic Veno-Occlusive Disease | 2 | 2022 | 220 | 0.310 |
Why?
|
Remission Induction | 4 | 2019 | 2407 | 0.310 |
Why?
|
Survival Rate | 11 | 2021 | 12870 | 0.300 |
Why?
|
GPI-Linked Proteins | 2 | 2024 | 473 | 0.300 |
Why?
|
Quinazolines | 1 | 2014 | 1373 | 0.290 |
Why?
|
Bone Marrow Cells | 1 | 2015 | 2414 | 0.290 |
Why?
|
Lymphoma | 1 | 2017 | 1907 | 0.290 |
Why?
|
Peptides | 1 | 2019 | 4353 | 0.290 |
Why?
|
Bone Marrow Transplantation | 5 | 2023 | 2709 | 0.290 |
Why?
|
Ovarian Neoplasms | 1 | 2024 | 4907 | 0.280 |
Why?
|
Immunotherapy | 6 | 2024 | 4738 | 0.270 |
Why?
|
Health Personnel | 1 | 2020 | 3380 | 0.270 |
Why?
|
Immunosuppressive Agents | 7 | 2021 | 4209 | 0.270 |
Why?
|
Proteins | 3 | 2018 | 6006 | 0.270 |
Why?
|
K562 Cells | 4 | 2024 | 644 | 0.270 |
Why?
|
Interferon-gamma | 3 | 2015 | 3164 | 0.260 |
Why?
|
Male | 44 | 2024 | 364902 | 0.250 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2021 | 646 | 0.250 |
Why?
|
Epstein-Barr Virus Infections | 2 | 2023 | 617 | 0.250 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2024 | 3617 | 0.250 |
Why?
|
Female | 44 | 2024 | 397089 | 0.240 |
Why?
|
HLA-A2 Antigen | 2 | 2022 | 208 | 0.240 |
Why?
|
Cell Line, Tumor | 8 | 2024 | 17135 | 0.230 |
Why?
|
Cardiomyopathies | 1 | 2017 | 2056 | 0.230 |
Why?
|
Virus Diseases | 3 | 2021 | 723 | 0.230 |
Why?
|
Antiviral Agents | 2 | 2014 | 3064 | 0.230 |
Why?
|
Registries | 2 | 2019 | 8379 | 0.230 |
Why?
|
Adolescent | 22 | 2024 | 89184 | 0.220 |
Why?
|
Liver Transplantation | 1 | 2016 | 2400 | 0.220 |
Why?
|
Survival Analysis | 6 | 2019 | 10117 | 0.210 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
Physicians | 1 | 2020 | 4614 | 0.200 |
Why?
|
Adrenergic Agents | 1 | 2022 | 73 | 0.200 |
Why?
|
Acute Disease | 5 | 2021 | 7242 | 0.200 |
Why?
|
Haplotypes | 3 | 2017 | 2724 | 0.200 |
Why?
|
Antigens, CD34 | 1 | 2024 | 656 | 0.200 |
Why?
|
Graft Survival | 3 | 2018 | 3900 | 0.200 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13697 | 0.190 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2021 | 5336 | 0.190 |
Why?
|
Herpesviridae | 1 | 2021 | 104 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9433 | 0.180 |
Why?
|
Chimerism | 1 | 2021 | 156 | 0.180 |
Why?
|
Single-Chain Antibodies | 1 | 2020 | 114 | 0.170 |
Why?
|
Heterocyclic Compounds | 1 | 2021 | 245 | 0.170 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1643 | 0.170 |
Why?
|
BK Virus | 1 | 2020 | 120 | 0.160 |
Why?
|
Adoptive Transfer | 3 | 2016 | 824 | 0.160 |
Why?
|
Bone Marrow | 3 | 2019 | 2929 | 0.160 |
Why?
|
Graft vs Leukemia Effect | 2 | 2020 | 121 | 0.150 |
Why?
|
Treatment Failure | 1 | 2024 | 2663 | 0.150 |
Why?
|
Blood Donors | 2 | 2019 | 344 | 0.150 |
Why?
|
Dermatitis | 1 | 2019 | 203 | 0.150 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 1558 | 0.140 |
Why?
|
Natural Killer T-Cells | 1 | 2021 | 318 | 0.140 |
Why?
|
Ustilaginales | 1 | 2017 | 1 | 0.140 |
Why?
|
Patient Care Management | 1 | 2020 | 304 | 0.140 |
Why?
|
Transplantation, Autologous | 2 | 2021 | 2127 | 0.140 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2020 | 4646 | 0.140 |
Why?
|
Genes, Neoplasm | 1 | 2019 | 370 | 0.140 |
Why?
|
Community-Acquired Infections | 1 | 2021 | 473 | 0.140 |
Why?
|
Dermatomycoses | 1 | 2017 | 45 | 0.140 |
Why?
|
Sulfonamides | 2 | 2024 | 1980 | 0.140 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2016 | 56 | 0.140 |
Why?
|
Fungemia | 1 | 2017 | 57 | 0.140 |
Why?
|
Viremia | 2 | 2016 | 725 | 0.130 |
Why?
|
Recombinant Fusion Proteins | 4 | 2018 | 3731 | 0.130 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 8634 | 0.130 |
Why?
|
Lymphoma, T-Cell | 1 | 2019 | 303 | 0.130 |
Why?
|
Lymphoproliferative Disorders | 1 | 2020 | 529 | 0.130 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 2 | 2022 | 896 | 0.130 |
Why?
|
Immunity, Innate | 4 | 2022 | 3078 | 0.130 |
Why?
|
Nitriles | 1 | 2021 | 984 | 0.130 |
Why?
|
Yeasts | 1 | 2017 | 279 | 0.130 |
Why?
|
Premedication | 1 | 2016 | 246 | 0.130 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2017 | 238 | 0.130 |
Why?
|
Janus Kinase 1 | 1 | 2015 | 107 | 0.120 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12558 | 0.120 |
Why?
|
Treatment Outcome | 8 | 2021 | 65379 | 0.120 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2017 | 342 | 0.120 |
Why?
|
Anemia, Aplastic | 1 | 2017 | 231 | 0.120 |
Why?
|
Mucositis | 1 | 2016 | 108 | 0.120 |
Why?
|
Interleukin-18 | 2 | 2014 | 251 | 0.120 |
Why?
|
Age Factors | 4 | 2024 | 18471 | 0.120 |
Why?
|
Cytokine-Induced Killer Cells | 1 | 2014 | 6 | 0.120 |
Why?
|
Neuroblastoma | 1 | 2022 | 1266 | 0.110 |
Why?
|
Heparin | 1 | 2021 | 1636 | 0.110 |
Why?
|
Mice | 8 | 2024 | 82017 | 0.110 |
Why?
|
Incidence | 9 | 2023 | 21544 | 0.110 |
Why?
|
Primary Myelofibrosis | 1 | 2015 | 209 | 0.110 |
Why?
|
Interleukin-12 | 2 | 2014 | 577 | 0.110 |
Why?
|
Respiratory Tract Infections | 1 | 2021 | 1014 | 0.110 |
Why?
|
Ligands | 2 | 2019 | 3283 | 0.110 |
Why?
|
Stem Cell Transplantation | 1 | 2022 | 1602 | 0.110 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily D | 1 | 2012 | 30 | 0.110 |
Why?
|
Receptors, Interleukin-12 | 1 | 2012 | 26 | 0.110 |
Why?
|
Receptors, Interleukin-18 | 1 | 2012 | 25 | 0.100 |
Why?
|
Isoantibodies | 1 | 2017 | 682 | 0.100 |
Why?
|
Piperidines | 1 | 2021 | 1659 | 0.100 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily C | 1 | 2012 | 38 | 0.100 |
Why?
|
L-Selectin | 1 | 2013 | 212 | 0.100 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2533 | 0.100 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 306 | 0.100 |
Why?
|
Necrosis | 1 | 2017 | 1621 | 0.100 |
Why?
|
Heart Failure | 1 | 2017 | 11858 | 0.100 |
Why?
|
Receptors, Interleukin-2 | 1 | 2014 | 564 | 0.100 |
Why?
|
Janus Kinase 2 | 1 | 2015 | 560 | 0.100 |
Why?
|
Exanthema | 1 | 2017 | 503 | 0.100 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2024 | 1889 | 0.100 |
Why?
|
Adipocytes | 1 | 2019 | 1200 | 0.100 |
Why?
|
Antifungal Agents | 1 | 2017 | 759 | 0.100 |
Why?
|
Receptors, KIR | 2 | 2024 | 114 | 0.100 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1428 | 0.090 |
Why?
|
Hodgkin Disease | 1 | 2019 | 1386 | 0.090 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15455 | 0.090 |
Why?
|
Netherlands | 1 | 2016 | 2274 | 0.090 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2676 | 0.090 |
Why?
|
Pyrazoles | 1 | 2021 | 2021 | 0.090 |
Why?
|
Transplantation Immunology | 1 | 2013 | 538 | 0.090 |
Why?
|
Myeloproliferative Disorders | 1 | 2017 | 613 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1943 | 0.090 |
Why?
|
Cell Proliferation | 3 | 2016 | 10478 | 0.090 |
Why?
|
Propensity Score | 1 | 2018 | 1962 | 0.090 |
Why?
|
Syndrome | 1 | 2016 | 3275 | 0.080 |
Why?
|
Animals | 9 | 2024 | 169337 | 0.080 |
Why?
|
Mice, Inbred NOD | 3 | 2021 | 1839 | 0.080 |
Why?
|
Lectins, C-Type | 1 | 2012 | 591 | 0.080 |
Why?
|
Pyrimidines | 1 | 2021 | 3048 | 0.080 |
Why?
|
Lymphoma, B-Cell | 1 | 2015 | 945 | 0.080 |
Why?
|
Chronic Disease | 5 | 2024 | 9379 | 0.080 |
Why?
|
Bacterial Infections | 1 | 2016 | 1397 | 0.080 |
Why?
|
Vidarabine | 2 | 2021 | 337 | 0.080 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2017 | 1751 | 0.080 |
Why?
|
Flow Cytometry | 2 | 2023 | 5900 | 0.070 |
Why?
|
Antigens, CD | 2 | 2022 | 4031 | 0.070 |
Why?
|
Benzimidazoles | 1 | 2013 | 864 | 0.070 |
Why?
|
DNA Methylation | 1 | 2021 | 4421 | 0.070 |
Why?
|
Secondary Prevention | 1 | 2013 | 1476 | 0.070 |
Why?
|
Protein Transport | 1 | 2013 | 1958 | 0.070 |
Why?
|
Neutrophils | 1 | 2020 | 3785 | 0.070 |
Why?
|
Coculture Techniques | 2 | 2023 | 1342 | 0.070 |
Why?
|
Herpesvirus 4, Human | 2 | 2023 | 1082 | 0.070 |
Why?
|
Interleukin-6 | 1 | 2016 | 3230 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2952 | 0.060 |
Why?
|
Donor Selection | 2 | 2019 | 240 | 0.060 |
Why?
|
Macrophages | 1 | 2021 | 5796 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2020 | 5800 | 0.060 |
Why?
|
Simplexvirus | 1 | 2009 | 805 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2022 | 7880 | 0.060 |
Why?
|
Risk | 2 | 2016 | 9636 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4588 | 0.060 |
Why?
|
Cytarabine | 2 | 2017 | 697 | 0.060 |
Why?
|
Mutation | 2 | 2022 | 30228 | 0.060 |
Why?
|
Protein Processing, Post-Translational | 1 | 2013 | 1967 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6541 | 0.060 |
Why?
|
Peptide Fragments | 1 | 2017 | 5151 | 0.060 |
Why?
|
Echocardiography | 1 | 2017 | 5044 | 0.060 |
Why?
|
Time Factors | 3 | 2017 | 40272 | 0.060 |
Why?
|
Cell Membrane | 1 | 2013 | 3663 | 0.050 |
Why?
|
Cells, Cultured | 3 | 2014 | 19022 | 0.050 |
Why?
|
Risk Factors | 5 | 2020 | 74962 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39407 | 0.050 |
Why?
|
B-Cell Maturation Antigen | 1 | 2024 | 149 | 0.050 |
Why?
|
Stroke Volume | 1 | 2017 | 5619 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 99 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 2018 | 1019 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3722 | 0.050 |
Why?
|
Comorbidity | 1 | 2017 | 10588 | 0.050 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2021 | 317 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 263 | 0.050 |
Why?
|
Cohort Studies | 2 | 2015 | 41795 | 0.050 |
Why?
|
Busulfan | 1 | 2021 | 259 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 136 | 0.040 |
Why?
|
Immunologic Factors | 2 | 2022 | 1597 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14737 | 0.040 |
Why?
|
Mice, SCID | 2 | 2017 | 2632 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2021 | 6318 | 0.040 |
Why?
|
Ohio | 1 | 2021 | 328 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12092 | 0.040 |
Why?
|
Benzylamines | 1 | 2021 | 251 | 0.040 |
Why?
|
Fever | 2 | 2017 | 1620 | 0.040 |
Why?
|
Tacrolimus | 1 | 2023 | 750 | 0.040 |
Why?
|
Chemokine CXCL12 | 1 | 2021 | 457 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 3212 | 0.040 |
Why?
|
Child, Preschool | 3 | 2021 | 42650 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2015 | 5708 | 0.040 |
Why?
|
Gene Expression Regulation | 2 | 2014 | 11918 | 0.040 |
Why?
|
Child | 5 | 2021 | 80891 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 892 | 0.040 |
Why?
|
Antigen Presentation | 1 | 2023 | 1251 | 0.040 |
Why?
|
Missouri | 1 | 2017 | 113 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20224 | 0.040 |
Why?
|
Cladribine | 1 | 2017 | 34 | 0.040 |
Why?
|
MicroRNAs | 1 | 2013 | 3804 | 0.040 |
Why?
|
Trichosporon | 1 | 2017 | 9 | 0.040 |
Why?
|
Filgrastim | 1 | 2017 | 131 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2017 | 148 | 0.040 |
Why?
|
Idarubicin | 1 | 2017 | 59 | 0.040 |
Why?
|
Cryptococcus | 1 | 2017 | 28 | 0.040 |
Why?
|
Aged, 80 and over | 5 | 2021 | 59686 | 0.030 |
Why?
|
Saccharomyces | 1 | 2017 | 62 | 0.030 |
Why?
|
Echinocandins | 1 | 2017 | 53 | 0.030 |
Why?
|
Signal Transduction | 3 | 2017 | 23631 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2024 | 1795 | 0.030 |
Why?
|
Lipopeptides | 1 | 2017 | 71 | 0.030 |
Why?
|
Nuclear Family | 1 | 2018 | 311 | 0.030 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2021 | 632 | 0.030 |
Why?
|
Amphotericin B | 1 | 2017 | 143 | 0.030 |
Why?
|
Receptors, CXCR4 | 1 | 2021 | 729 | 0.030 |
Why?
|
Cell Degranulation | 1 | 2017 | 277 | 0.030 |
Why?
|
Living Donors | 1 | 2021 | 651 | 0.030 |
Why?
|
Cryopreservation | 1 | 2021 | 733 | 0.030 |
Why?
|
Graft Rejection | 2 | 2021 | 4505 | 0.030 |
Why?
|
Steroids | 1 | 2021 | 937 | 0.030 |
Why?
|
5-Methylcytosine | 1 | 2016 | 147 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1855 | 0.030 |
Why?
|
Etoposide | 1 | 2017 | 639 | 0.030 |
Why?
|
Adenine | 1 | 2021 | 993 | 0.030 |
Why?
|
Perforin | 1 | 2015 | 167 | 0.030 |
Why?
|
Drug Evaluation | 1 | 2016 | 642 | 0.030 |
Why?
|
Drug Resistance | 1 | 2021 | 1595 | 0.030 |
Why?
|
Phenotype | 2 | 2024 | 16721 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2021 | 954 | 0.030 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2015 | 306 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2020 | 839 | 0.030 |
Why?
|
Mycoses | 1 | 2017 | 386 | 0.030 |
Why?
|
Granzymes | 1 | 2015 | 278 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2017 | 2017 | 0.030 |
Why?
|
Electroencephalography | 1 | 2009 | 6317 | 0.030 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2013 | 220 | 0.030 |
Why?
|
Fetal Blood | 1 | 2020 | 1361 | 0.030 |
Why?
|
Cell Lineage | 1 | 2022 | 2574 | 0.030 |
Why?
|
STAT5 Transcription Factor | 1 | 2014 | 268 | 0.030 |
Why?
|
Integrins | 1 | 2017 | 843 | 0.030 |
Why?
|
Calcineurin | 1 | 2013 | 236 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2020 | 1999 | 0.030 |
Why?
|
Neutropenia | 1 | 2017 | 893 | 0.020 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 687 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2846 | 0.020 |
Why?
|
Lymphocytes | 1 | 2019 | 2611 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1890 | 0.020 |
Why?
|
Drug Synergism | 1 | 2015 | 1762 | 0.020 |
Why?
|
Models, Immunological | 1 | 2013 | 518 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2017 | 15649 | 0.020 |
Why?
|
Transduction, Genetic | 1 | 2013 | 902 | 0.020 |
Why?
|
Lentivirus | 1 | 2013 | 519 | 0.020 |
Why?
|
Infant | 1 | 2013 | 36510 | 0.020 |
Why?
|
Prospective Studies | 3 | 2021 | 54920 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3939 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2013 | 1524 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3431 | 0.020 |
Why?
|
Genotype | 1 | 2024 | 13042 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 4859 | 0.020 |
Why?
|
Prognosis | 2 | 2021 | 30022 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2015 | 14481 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2020 | 18362 | 0.020 |
Why?
|
Interleukins | 1 | 2013 | 796 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4450 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8731 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8902 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5916 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4411 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 11854 | 0.020 |
Why?
|
Anticoagulants | 1 | 2021 | 4843 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2013 | 2038 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9261 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2014 | 2394 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8562 | 0.020 |
Why?
|
NF-kappa B | 1 | 2013 | 2489 | 0.020 |
Why?
|
RNA Interference | 1 | 2013 | 2836 | 0.020 |
Why?
|
Biopsy | 1 | 2017 | 6808 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2017 | 3407 | 0.010 |
Why?
|
Up-Regulation | 1 | 2013 | 4142 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2013 | 2884 | 0.010 |
Why?
|
Genetic Vectors | 1 | 2013 | 3413 | 0.010 |
Why?
|
United States | 2 | 2021 | 73150 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 36849 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8753 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15939 | 0.010 |
Why?
|
Disease Progression | 1 | 2015 | 13646 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 24318 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2013 | 22355 | 0.010 |
Why?
|